Brought to you by 
Roche teams with Galapagos in multi-year COPD alliance; terminated
08 Dec 2015
Executive Summary
In a worldwide, multi-year deal, Roche has received exclusive options to license small molecules against chronic obstructive pulmonary disease (COPD) targets identified by Belgian drug discovery firm Galapagos NV.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche teams with Galapagos in multi-year COPD alliance; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice